Definitive Healthcare Corp. (DH)

NASDAQ: DH · Real-Time Price · USD
0.8970
-0.0103 (-1.14%)
At close: Jun 5, 2026, 4:00 PM EDT
0.9270
+0.0300 (3.34%)
After-hours: Jun 5, 2026, 6:39 PM EDT
Market Cap128.94M -73.3%
Revenue (ttm)238.26M -3.9%
Net Income-170.33M
EPS-1.63
Shares Out 143.75M
PE Ration/a
Forward PE5.30
Dividendn/a
Ex-Dividend Daten/a
Volume320,787
Open0.9137
Previous Close0.9073
Day's Range0.8552 - 0.9818
52-Week Range0.8033 - 4.7000
Beta1.34
AnalystsHold
Price Target2.46 (+174.25%)
Earnings DateMay 7, 2026

About DH

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution. The company’s platform consists of various functional areas, such as sales, marketing, clinical research and product development, strategy, talent acquisition, and physician... [Read more]

Sector Healthcare
IPO Date Sep 15, 2021
Employees 686
Stock Exchange NASDAQ
Ticker Symbol DH
Full Company Profile

Financial Performance

In 2025, Definitive Healthcare's revenue was $241.52 million, a decrease of -4.24% compared to the previous year's $252.20 million. Losses were -$138.93 million, -66.37% less than in 2024.

Financial Statements

Analyst Summary

According to 10 analysts, the average rating for DH stock is "Hold." The 12-month stock price target is $2.46, which is an increase of 174.25% from the latest price.

Price Target
$2.46
(174.25% upside)
Analyst Consensus: Hold
Stock Forecasts

News

Definitive Healthcare advances data platform and integrations to deliver smarter healthcare insights

Latest enhancements provide deeper medical claims insights, a new integration with HubSpot®, seamless access to healthcare professional (HCP) data directly in Salesforce, and AI search capabilities La...

15 days ago - GlobeNewsWire

Definitive Healthcare price target lowered to $1.10 from $1.30 at Baird

Baird lowered the firm’s price target on Definitive Healthcare (DH) to $1.10 from $1.30 and keeps a Neutral rating on the shares. The firm updated its model following Q1 results.

4 weeks ago - TheFly

Definitive Healthcare reports Q1 adjusted EPS 6c, consensus 3c

Reports Q1 revenue $55.93M, consensus $54.98M. “Definitive Healthcare (DH) started 2026 on a solid note, with financial results at or above the high end of our guidance ranges. We continue…

4 weeks ago - TheFly

Definitive Healthcare sees Q2 adjusted EPS 3c-4c, consensus 4c

Sees Q2 revenue $55M-$56M, consensus $55.47M.

4 weeks ago - TheFly

Definitive Healthcare raises FY26 adjusted EPS view to 16c-19c from 14c-17c

Consensus 17c. Backs FY26 revenue view $220M-$226M, consensus $223.64M. Backs FY26 adjusted EBITDA view $13.5M-$14.5M.

4 weeks ago - TheFly

Definitive Healthcare Earnings Call Transcript: Q1 2026

Q1 2026 results were at or above guidance, with revenue down 6% year-over-year and strong margin expansion. Provider and diversified segments grew, offsetting life sciences declines, while AI and integration investments are expected to drive future growth.

4 weeks ago - Transcripts

Definitive Healthcare Slides: Q1 2026

Definitive Healthcare has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 7, 2026.

4 weeks ago - Filings

Definitive Healthcare Earnings release: Q1 2026

Definitive Healthcare released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.

4 weeks ago - Filings

Definitive Healthcare Quarterly report: Q1 2026

Definitive Healthcare has published its Q1 2026 quarterly earnings report on May 7, 2026.

4 weeks ago - Filings

Definitive Healthcare Reports Financial Results for First Quarter 2026

FRAMINGHAM, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. (“Definitive Healthcare” or the “Company”) (Nasdaq: DH), an industry leader in healthcare market data and analytics, tod...

4 weeks ago - GlobeNewsWire

Definitive Healthcare Announces Timing of Its First Quarter 2026 Financial Results Conference Call and Webcast

FRAMINGHAM, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. (“Definitive Healthcare”) (Nasdaq: DH), an industry leader in healthcare market data and analytics, today announced th...

6 weeks ago - GlobeNewsWire

Definitive Healthcare Proxy statement: Proxy filing

Definitive Healthcare filed a proxy statement on April 23, 2026, providing details for shareholder voting and corporate governance matters.

6 weeks ago - Filings

Definitive Healthcare Proxy statement: Proxy filing

Definitive Healthcare filed a proxy statement on April 23, 2026, providing details for shareholder voting and corporate governance matters.

6 weeks ago - Filings

Definitive Healthcare price target lowered to $1 from $2.75 at Barclays

Barclays lowered the firm’s price target on Definitive Healthcare (DH) to $1 from $2.75 and keeps an Underweight rating on the shares. The firm updated models in healthcare technology to…

2 months ago - TheFly

Definitive Healthcare price target lowered to $3 from $6 at Deutsche Bank

Deutsche Bank lowered the firm’s price target on Definitive Healthcare (DH) to $3 from $6 and keeps a Hold rating on the shares.

3 months ago - TheFly

Definitive Healthcare price target lowered to $1.90 from $3 at Baird

Baird lowered the firm’s price target on Definitive Healthcare (DH) to $1.90 from $3 and keeps a Neutral rating on the shares. The firm updated its model following Q4 results.

3 months ago - TheFly

Definitive Healthcare price target lowered to $3 from $5 at Stifel

Stifel lowered the firm’s price target on Definitive Healthcare (DH) to $3 from $5 and keeps a Buy rating on the shares.

3 months ago - TheFly

Definitive Healthcare price target lowered to $2 from $3 at Stephens

Stephens lowered the firm’s price target on Definitive Healthcare (DH) to $2 from $3 and keeps an Equal Weight rating on the shares. Turnaround efforts should drive Life Sciences revenue…

3 months ago - TheFly

Definitive Healthcare price target lowered to $2 from $3 at Stephens

Stephens lowered the firm’s price target on Definitive Healthcare (DH) to $2 from $3 and keeps an Equal Weight rating on the shares. Turnaround efforts should drive Life Sciences revenue…

3 months ago - TheFly

Definitive Healthcare price target lowered to $3 from $4 at Canaccord

Canaccord lowered the firm’s price target on Definitive Healthcare (DH) to $3 from $4 and keeps a Hold rating on the shares. The firm said they reported Q4 results that…

3 months ago - TheFly

Definitive Healthcare reports Q4 adjusted EPS 6c, consensus 6c

Reports Q4 revenue $61.5M, consensus $59.57M. “Our fourth quarter results were at or above the high end of our guidance ranges on both the top and bottom line, demonstrating the…

3 months ago - TheFly

Definitive Healthcare sees Q1 adjusted EPS 3c, consensus 6c

Sees Q1 revenue $54.0M-$56.0M, consensus $57.23M.

3 months ago - TheFly

Definitive Healthcare sees FY26 adjusted EPS 14c-17c, consensus 26c

Sees FY26 revenue $220.0M-$226.0M, consensus $233.61M.

3 months ago - TheFly

Definitive Healthcare Earnings Call Transcript: Q4 2025

Q4 revenue and profitability exceeded guidance despite a 1% year-over-year revenue decline, with strong cash flow and margin expansion. Retention rates improved, claims data volumes were restored, and diversified/provider segments returned to growth, while 2026 guidance reflects continued top-line pressure but improved operational execution.

3 months ago - Transcripts

Definitive Healthcare Annual report: Q4 2025

Definitive Healthcare has published its Q4 2025 annual report on February 26, 2026.

3 months ago - Filings